Vaccine against peanut allergy based on engineered Virus-Like-Particles displaying single major peanut allergens.

[1]  M. Maurer,et al.  Allergen-Immuntherapie in der aktuellen Covid-19-Pandemiea, b, c , 2020, Allergo Journal.

[2]  J. Foerster,et al.  Virus-Like Particle-Mediated Vaccination against Interleukin-13 May Harbour General Anti-Allergic Potential beyond Atopic Dermatitis , 2020, Viruses.

[3]  Ina Baļķe,et al.  Recent Advances in the Use of Plant Virus-Like Particles as Vaccines , 2020, Viruses.

[4]  R. Valenta,et al.  Allergen-Specific Antibodies Regulate Secondary Allergen-Specific Immune Responses , 2019, Front. Immunol..

[5]  William H. Yang,et al.  AR101 Oral Immunotherapy for Peanut Allergy , 2018, The New England journal of medicine.

[6]  L. Eichenfield.  Faculty Opinions recommendation of Randomized trial of peanut consumption in infants at risk for peanut allergy. , 2018, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[7]  J. Baker,et al.  Nanoemulsion adjuvant–driven redirection of TH2 immunity inhibits allergic reactions in murine models of peanut allergy , 2018, The Journal of allergy and clinical immunology.

[8]  A. Murphy,et al.  Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement , 2018, Nature Communications.

[9]  M. Vogel,et al.  An unexpected protective role of low‐affinity allergen‐specific IgG through the inhibitory receptor Fc&ggr;RIIb , 2018, The Journal of allergy and clinical immunology.

[10]  M. Vogel,et al.  Allergens displayed on virus‐like particles are highly immunogenic but fail to activate human mast cells , 2018, Allergy.

[11]  D. Stuart,et al.  Incorporation of tetanus-epitope into virus-like particles achieves vaccine responses even in older recipients in models of psoriasis, Alzheimer’s and cat allergy , 2017, npj Vaccines.

[12]  M. Bachmann,et al.  Major findings and recent advances in virus-like particle (VLP)-based vaccines. , 2017, Seminars in immunology.

[13]  M. Sears,et al.  Timing of food introduction and development of food sensitization in a prospective birth cohort , 2017, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[14]  M. Vogel,et al.  A novel bispecific DARPin targeting FcγRIIB and FcεRI‐bound IgE inhibits allergic responses , 2017, Allergy.

[15]  T. Kündig,et al.  Allergen‐specific immunotherapy: is it vaccination against toxins after all? , 2017, Allergy.

[16]  P. Dubreuil,et al.  Trans-inhibition of activation and proliferation signals by Fc receptors in mast cells and basophils , 2016, Science Signaling.

[17]  I. Pali-Schöll,et al.  The concept of allergen-associated molecular patterns (AAMP). , 2016, Current opinion in immunology.

[18]  Steve L. Taylor,et al.  Allergenicity attributes of different peanut market types. , 2016, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[19]  R. Wood,et al.  Food allergen immunotherapy: Current status and prospects for the future. , 2016, The Journal of allergy and clinical immunology.

[20]  Carsten Flohr,et al.  Randomized Trial of Introduction of Allergenic Foods in Breast-Fed Infants. , 2016, The New England journal of medicine.

[21]  B. Vickery,et al.  Current Options for the Treatment of Food Allergy. , 2015, Pediatric clinics of North America.

[22]  A. Henning,et al.  Sublingual immunotherapy for peanut allergy: Long-term follow-up of a randomized multicenter trial. , 2015, The Journal of allergy and clinical immunology.

[23]  S. Durham,et al.  IgG4 inhibits peanut-induced basophil and mast cell activation in peanut-tolerant children sensitized to peanut major allergens , 2015, The Journal of allergy and clinical immunology.

[24]  R. Pieters,et al.  Heterogeneous responses and cross reactivity between the major peanut allergens Ara h 1, 2,3 and 6 in a mouse model for peanut allergy , 2015, Clinical and Translational Allergy.

[25]  G. Roberts,et al.  Randomized Trial of Peanut Consumption in Infants at Risk for Peanut Allergy , 2015, Pediatrics.

[26]  William H. Yang,et al.  Epicutaneous Immunotherapy (EPIT) Is Effective and Safe to Treat Peanut Allergy: A Multi-National Double-Blind Placebo-Controlled Randomized Phase IIb Trial , 2015 .

[27]  C. Palmer,et al.  Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial , 2014, The Lancet.

[28]  L. Pedersen,et al.  The Molecular Basis of Peanut Allergy , 2014, Current Allergy and Asthma Reports.

[29]  A. Sheikh,et al.  The epidemiology of food allergy in Europe: a systematic review and meta‐analysis , 2014, Allergy.

[30]  C. Radauer,et al.  IgE cross-reactivity between the major peanut allergen Ara h 2 and the non-homologous allergens Ara h 1 and Ara h 3 , 2013, Clinical and Translational Allergy.

[31]  S. Durham,et al.  Rhinitis , sinusitis , and upper airway disease SQ-standardized sublingual grass immunotherapy : Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial , 2012 .

[32]  A. Cummings,et al.  The psychosocial impact of food allergy and food hypersensitivity in children, adolescents and their families: a review , 2010, Allergy.

[33]  M. Bachmann,et al.  Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy , 2009, The Journal of experimental medicine.

[34]  S. Durham,et al.  Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. , 2008, The Journal of allergy and clinical immunology.

[35]  H. Malling,et al.  Side‐effects of allergen‐specific immunotherapy. A prospective multi‐centre study , 2006, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[36]  A. Kay,et al.  T Cell Epitope Immunotherapy Induces a CD4+ T Cell Population with Regulatory Activity , 2005, PLoS medicine.

[37]  S. Durham,et al.  Mechanisms of immunotherapy: IgG revisited , 2004, Current opinion in allergy and clinical immunology.

[38]  A. Burks,et al.  The natural progression of peanut allergy: Resolution and the possibility of recurrence. , 2003, The Journal of allergy and clinical immunology.

[39]  L. Burgart,et al.  Increased eosinophil infiltration and degranulation in colonic tissue from patients with collagenous colitis , 2001, American Journal of Gastroenterology.

[40]  L. Hültner,et al.  Murine Bone Marrow-Derived Mast Cells as Potent Producers of IL-9: Costimulatory Function of IL-10 and kit Ligand in the Presence of IL-11 , 2000, The Journal of Immunology.

[41]  M. Willheim,et al.  Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T‐cell clones specific for Phi p 1, a major grass pollen allergen , 1997, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[42]  Huabin Li,et al.  Blockade of peanut allergy with a novel Ara h 2-Fcγ fusion protein in mice. , 2013, The Journal of allergy and clinical immunology.

[43]  A. Burks,et al.  Peanut oral immunotherapy modifies IgE and IgG4 responses to major peanut allergens. , 2013, The Journal of allergy and clinical immunology.

[44]  A. Woodcock,et al.  Allergy or tolerance in children sensitized to peanut: prevalence and differentiation using component-resolved diagnostics. , 2010, The Journal of allergy and clinical immunology.